Antibody–drug conjugates: Recent advances in payloads
TLDR
In this paper , the authors summarized the recent research advances of traditional and novel ADC payloads with main focus on the structure-activity relationship studies, co-crystal structures, and designing strategies.About:
This article is published in Acta Pharmaceutica Sinica B.The article was published on 2023-06-01 and is currently open access. It has received 0 citations till now. The article focuses on the topics: Payload (computing) & Drug development.read more
References
More filters
Journal ArticleDOI
The BCL-2 protein family: opposing activities that mediate cell death
TL;DR: New insights into interactions among BCL-2 family proteins reveal how these proteins are regulated, but a unifying hypothesis for the mechanisms they use to activate caspases remains elusive.
Journal ArticleDOI
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Gail Lewis Phillips,Guangmin Li,Debra L. Dugger,Lisa Crocker,Kathryn Parsons,Elaine Mai,Walter A. Blattler,John M. Lambert,Ravi V. J. Chari,Robert J. Lutz,Wai Lee T. Wong,Frederic S. Jacobson,Hartmut Koeppen,Ralph H. Schwall,Sara R. Kenkare-Mitra,Susan D. Spencer,Mark X. Sliwkowski +16 more
TL;DR: In vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymerizing agents) conjugates using disulfide and thioether linkers are determined andtrastuzuab-MCC-DM1 shows greater activity compared with nonconjugated trastumab while maintaining selectivity for HER2-overexpressing tumor cells.
Journal ArticleDOI
Microtubule-binding agents: a dynamic field of cancer therapeutics
Charles Dumontet,Mary Ann Jordan +1 more
TL;DR: The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties, and the three main objectives are enhanced tumour specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms.
Journal ArticleDOI
Paul Ehrlich's magic bullet concept: 100 years of progress.
Klaus Strebhardt,Axel Ullrich +1 more
TL;DR: The intellectual foundations of the development of cancer drug development are revisited, as many have shown great clinical success and are therefore appropriate to revisit.
Journal ArticleDOI
The mechanism of topoisomerase I poisoning by a camptothecin analog
Bart L. Staker,Kathryn Hjerrild,Michael D. Feese,Craig A. Behnke,Alex B. Burgin,Lance Stewart +5 more
TL;DR: The x-ray crystal structure of human topoisomerase I covalently joined to double-stranded DNA and bound to the clinically approved anticancer agent Topotecan suggests that there are at least two classes of mutations that can produce a drug-resistant enzyme.